Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702623 · ClinicalTrials.gov registry record · Phase 1
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
A Phase 1 study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01702623 is a Phase 1 study that has completed, run by Roxane Laboratories. The registered enrollment target is 64 participants.
The verdict
NCT01702623, a Phase 1 study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fasted conditions.
Interventions
- DRUG Oxcarbazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702623
The ClinicalTrials.gov registry entry for NCT01702623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxcarbazepine is the first listed.
NCT01702623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01702623 about?
NCT01702623 is a clinical study titled "Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fasted conditions.
What is the current status of trial NCT01702623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2009-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT01702623?
The interventions under investigation include: Oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT01702623?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.